NOVEL THIAMINE-ORGANIC ACID SALT

Abstract

The present disclosure relates to novel thiamine-organic acid salt, and the method of making the novel thiamine-organic acid salt.

Claims

1. A thiamine-organic acid salt of formula I: ##STR00013## wherein A represents an organic acid moiety comprising two [COO.sup.] groups, or an organic acid moiety comprising one COOH group and one COO group, or a nicotinate group; i is 1 to 4; j is 1 to 12; k is 0-4; and m is 1-2, wherein i=k+2 when [A].sub.m represents one organic acid moiety comprising two [COO.sup.] groups or two organic acid moiety each comprising one COOH group and one COO.sup.group, or i=k+1 when [A].sub.m represents one organic acid moiety comprising one COOH group and one COO.sup. group, or a nicotinate group.

2. The thiamine-organic acid salt of claim 1, wherein A represents [(.sup.OOC)-L-(COO.sup.)], or [(OOC)-L-(COOH)], or a nicotinate group, and L is C.sub.0-C.sub.8 saturated or unsaturated hydrocarbon linker.

3. The thiamine-organic acid salt of claim 2, wherein L is a bond, CH.sub.2, CH.sub.2-CH.sub.2, or CH=CH; i is 2 or 4; j is 1-10, and k is 0, 1, or 2.

4. The thiamine-organic acid salt of claim 1, wherein the co-crystal is selected from the group consisting of: ##STR00014##

5. The thiamine-organic acid salt of claim 1, wherein the thiamine-organic acid salt is single crystal.

6. A method of making the thiamine-organic acid salt of claim 1, wherein the method comprises: a) preparing a silver salt Ag.sub.2A or AgA, wherein A represents an organic acid moiety comprising two [COO.sup.] groups in the silver salt Ag.sub.2A and wherein A represents an organic acid moiety comprising a nicotinate group or an organic acid moiety comprising one [COO.sup.] group and one [COOH] groups in the silver salt AgA; b) preparing a solution comprising thiamine cations and A by contacting a aqueous solution comprising thiamine chloride with the silver salt prepared in step a); and c) preparing thiamine-organic acid salt of any of claim 1 by adding the solution comprising thiamine cations and A prepared in step b) to an organic solvent, and allowing the crystal of the thiamine salt/hydrate of claim 1 to grow.

7. The method of claim 6, wherein the organic solvent is acetone or tetrahydrofuran.

Description

DETAILED DESCRIPTION

[0015] For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to the embodiments. It will nevertheless be understood that no limitation of the scope of this disclosure is thereby intended.

[0016] In the present disclosure the term about can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.

[0017] In the present disclosure the term substantially can allow for a degree of variability in a value or range, for example, within 90%, within 95%, or within 99% of a stated value or of a stated limit of a range.

[0018] The present disclosure for the first time identified some unique and stable thiamine and organic acid salts.

[0019] In one embodiment, the present disclosure provides a thiamine-organic acid salt of formula I:

##STR00003##

wherein A represents an organic acid moiety comprising two [COO.sup.] groups, or an organic acid moiety comprising one COOH group and one COO group, or a nicotinate group;
i is 1 to 4;
j is 1 to 12;
k is 0-4; and
m is 1-2,
wherein i=k+2 when [A].sub.m represents one organic acid moiety comprising two [COO.sup.] groups or two organic acid moiety each comprising one COOH group and one COO.sup. group, or i=k+1 when [A].sub.m represents one organic acid moieties comprising one COOH group and one COO.sup. group, or a nicotinate group.

[0020] In one embodiment, the present disclosure provides a thiamine-organic acid salt of formula I:

##STR00004##

wherein A represents [(.sup.OOC)-L-(COO.sup.)], or [(.sup.OOC)-L-(COOH)], or a nicotinate group, and L is C.sub.0-C.sub.8 saturated or unsaturated hydrocarbon linker;
i is 1 to 4;
j is 1 to 12;
k is 0-4; and
m is 1-2,
wherein i=k+2 when [A].sub.m represents one organic acid moiety comprising two [COO.sup.] groups or two organic acid moiety each comprising one COOH group and one COO.sup.group, or i=k+1 when [A].sub.m represents one organic acid moiety comprising one COOH group and one COO group, or a nicotinate group.

[0021] In one embodiment, the present disclosure provides a thiamine-organic acid salt of formula I:

##STR00005##

wherein A represents [(.sup.OOC)-L-(COO.sup.)] or [(.sup.OOC)-L-(COOH)], or a nicotinate group, and L is a bond, CH.sub.2, CH.sub.2-CH.sub.2, or CH=CH; i is 2 or 4; j is 1-10, and k is 0, 1, or 2.

[0022] In one embodiment, the present disclosure provides a thiamine-organic acid salt of formula I, wherein the thiamine-organic acid salt is selected from the group consisting of:

##STR00006##

[0023] In one embodiment, the present disclosure provides a method of making the thiamine-organic acid salt of formula I, wherein the method comprises:

[0024] a) preparing a silver salt Ag.sub.2A or AgA, wherein A represents an organic acid moiety comprising two [COO.sup.] groups in the silver salt Ag.sub.2A and wherein A represents an organic acid moiety comprising a nicotinate group or an organic acid moiety comprising one [COO.sup.] group and one [COOH] groups in the silver salt AgA;

[0025] b) preparing a solution comprising thiamine cations and A by contacting a aqueous solution comprising thiamine chloride with the silver salt prepared in step a); and

[0026] c) preparing thiamine-organic acid salt by adding the solution comprising thiamine cations and A prepared in step b) to an organic solvent, and allowing the crystal of the thiamine salt/hydrate of claim 1 to nucleate and grow.

[0027] In one embodiment, the present disclosure provides a method of making the thiamine-organic acid salt of formula I, wherein the organic solvent may be but is not limited to acetone; tetrahydrofuran; aliphatic alcohols such as methanol, ethanol, isopropanol, butanol; esters such as ethyl acetate; ethers; alkanes such as hexane, heptane, or cyclohexane; halogenated solvents such as dichloromethane, chloroform, or carbon tetrachloride, or any combination thereof. In one aspect, the preferred solvent is acetone or tetrahydrofuran.

EXPERIMENTS

[0028] Single Crystal X-Ray Diffraction (SXD) analysis

[0029] Single crystal diffraction data were collected on a Bruker AXS D8 Quest diffractometer with a CMOS detector and graphite monochromated Mo K (=0.71073 ) or Cu K (=1.54178 ) radiation with an Oxford Cryosystem 800 temperature controller operating at 150 (2) K. Diffraction data were processed (cell refinement and data reduction) using Bruker Apex3 v2016.9-0 (Bruker, 2016), SAINT V8.37A (Bruker, 2016) software and structure solution and refinement were carried out by using SHELXS97 (Sheldrick, 2008), SHELXL2017/1 (Sheldrick, 2017), SHELXLE Rev859 (Hbschle et al., 2011).

[0030] Thermogravimetric Analysis

[0031] The weight loss profile as a function of heating a sample (thermogravimetric analysis) was generated using Q50 TGA (TA Instruments, New Castle, Del.). Approximately 3-6 mg sample was placed onto aluminum pans before loading onto platinum sample holders. Samples were heated from room temperature to 300 C. at the rate of 5 C./min. The furnace was purged with nitrogen gas. The thermogravimetric profile was plotted using the using the TA Universal Analysis software (TA Instruments, New Castle, Del.).

[0032] Dynamic Vapor Sorption (DVS)

[0033] Moisture sorption profiles were generated at 25 C. using an SGA-100 symmetrical gravimetric analyzer (TA Instrument, New Castle, Del.). The samples (5-20 mg) were exposed to 25% to 95% relative humidity (RH) at step size of 5% RH and from 95 to 99% RH at step size of 1% RH, with a maximum step time of 360 min. The equilibrium criteria were set to change of mass of less than 0.01% (w/w) for 5 min for each step. Nitrogen was used as the purge gas.

Example 1: Thiamine Succinate: Dithiamine Succinate Heptahydrate

[0034] ##STR00007##

[0035] Step 1: Preparation of Silver Succinate:

[0036] About 10 mmoles of disodium succinate hexahydrate was dissolved in approximately 6 ml water in a 20 mL glass vial. Two mL of a 5M solution of silver nitrate (10 mmoles) was added to the succinate solution with stirring. Silver succinate was formed as white precipitates which were collected on Nylon filters (Millipore, 0.2 m pore size) over a Buchner funnel. Vacuum was applied to accelerate the filtration process. The precipitates were washed 4 times with 2-3 mL of deionized water. The white precipitates so obtained were dried in an oven for 1 hour at 50 C., and stored protected from light to prevent discoloration (silver compounds are prone to discoloration on exposure to light).

[0037] Step 2: Preparation of Thiamine Chloride:

[0038] About one molar equivalent of thiamine chloride hydrochloride dissolved in water was mixed with one molar equivalent of sodium hydroxide and the resulting thiamine chloride was crystallized by addition of acetone to the aqueous solution. The thiamine chloride so obtained was purified by recrystallization from water-acetone mixture.

[0039] Step 3: Preparation of Thiamine Succinate:

[0040] About 576 mg thiamine chloride was dissolved in 3 ml water and 300 mg of silver succinate was added to this solution. The suspension obtained was centrifuged at 7200 g for 3 minutes and the resulting supernatant containing the thiamine cations and succinate anions was filtered through a Nylon filter (Millipore, 0.2 m pore size).

[0041] Step 4: Crystallization of Thiamine Succinate:

[0042] Approximately one ml of the thiamine succinate solution prepared in Step 3 was added dropwise to 10 ml of acetone in a 20 mL vial. The solution was stored in the freezer (20 C.) for 1 week. Needle shaped transparent crystals were obtained in the vial with 1:10 water-acetone. One of these crystals was used for single crystal XRD analysis, and was identified as Example 1: dithiamine succinate heptahydrate.

TABLE-US-00001 TABLE 1 Experimental details for Example 1 single crystal XRD Sample name Example 1 Crystal data Chemical formula 2(C.sub.12H.sub.17N.sub.4OS)C.sub.4H.sub.4O.sub.47(H.sub.2O) M.sub.r 772.89 Crystal system, space group Triclinic, P.sup. 1 Temperature (K) 150 a, b, c () 11.1565 (3), 12.5014 (4), 14.1668 (4) , , () 108.7195 (13), 90.1747 (15), 90.2162 (15) V (.sup.3) 1871.32 (10) Z 2 Radiation type Cu K (mm.sup.1) 1.91 Crystal size (mm) 0.55 0.21 0.09 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.462, 0.754 No. of measured, 34701, 7827, 6994 independent and observed [I > 2 (I)] reflections R.sub.int 0.087 (sin /).sub.max (.sup.1) 0.639 Refinement R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.051, 0.146, 1.08 No. of reflections 7827 No. of parameters 511 No. of restraints 14 H-atom treatment H atoms treated by a mixture of independent and constrained refinement .sub.max, .sub.min (e .sup.3) 0.50, 0.51

TABLE-US-00002 TABLE 2 Examples 2-5 were prepared with essentially the same method of making Example 1. Example Solvent for No. Thiamine-organic acid salt crystallization 2 [00008] tetrahydrofuran 3 [00009] acetone 4 [00010] tetrahydrofuran 5 [00011] acetone

TABLE-US-00003 TABLE 3 Experimental details for Example 2 single crystal XRD Sample name Example 2 Crystal data Chemical formula 2(C.sub.12H.sub.17N.sub.4OS)C.sub.4H.sub.3O.sub.4Cl3(H.sub.2O) M.sub.r 735.27 Crystal system, space Triclinic, P.sup. 1 group Temperature (K) 150 a, b, c () 11.6913 (6), 12.9090 (6), 13.2717 (7) , , () 114.5680 (16), 105.6584 (18), 95.3322 (19) V (.sup.3) 1705.25 (15) Z 2 Radiation type Mo K (mm.sup.1) 0.30 Crystal size (mm) 0.55 0.33 0.28 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.705, 0.747 No. of measured, 124509, 13011, 10187 independent and observed [I > 2 (I)] reflections R.sub.int 0.032 (sin /).sub.max (.sup.1) 0.771 Refinement R[F.sup.2 > 2 (F.sup.2)], wR(F.sup.2), S 0.038, 0.111, 1.03 No. of reflections 13011 No. of parameters 549 No. of restraints 261 H-atom treatment H atoms treated by a mixture of independent and constrained refinement .sub.max, .sub.min (e .sup.3) 0.42, 0.36

TABLE-US-00004 TABLE 4 Experimental details for Example 3 single crystal XRD Sample name Example 3 Crystal data Chemical formula 4(C.sub.12H.sub.17N.sub.4OS)C.sub.3H.sub.2O.sub.42(Cl)9(H.sub.2O) M.sub.r 1396.51 Crystal system, space Monoclinic, P2.sub.1/c group Temperature (K) 150 a, b, c () 11.9760 (8), 27.1164 (17), 11.1581 (7) A, , () 111.359 (2) V (.sup.3) 3374.7 (4) Z 2 Radiation type Mo K (mm.sup.1) 0.30 Crystal size (mm) 0.43 0.11 0.03 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.601, 0.746 No. of measured, 35002, 8187, 6997 independent and observed [I > 2 (I)] reflections R.sub.int 0.053 (sin /).sub.max (.sup.1) 0.667 Refinement R[F.sup.2 > 2 (F.sup.2)], 0.089, 0.215, 1.15 wR(F.sup.2), S No. of reflections 8187 No. of parameters 517 No. of restraints 39 H-atom treatment H atoms treated by a mixture of independent and constrained refinement w = 1/[.sup.2(F.sub.o.sup.2) + 21.0624P] where P = (F.sub.o.sup.2 + 2F.sub.c.sup.2)/3 .sub.max, .sub.min (e .sup.3) 0.88, 0.94

TABLE-US-00005 TABLE 5 Experimental details for Example 4 single crystal XRD Sample name Example 4 Crystal data Chemical formula 2(C.sub.12H.sub.17N.sub.4OS)C.sub.3H.sub.3O.sub.4Cl3(H.sub.2O) M.sub.r 723.26 Crystal system, space Triclinic, P.sup. 1 group Temperature (K) 150 a, b, c () 6.5349 (4), 11.2514 (7), 12.3863 (8) A, , () 113.370 (2), 91.661 (2), 92.763 (2) V (.sup.3) 833.89 (9) Z 1 Radiation type Mo K (mm.sup.1) 0.30 Crystal size (mm) 0.55 0.42 0.16 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.684, 0.747 No. of measured, 44039, 6337, 5585 independent and observed [I > 2 (I)] reflections R.sub.int 0.029 (sin /).sub.max (.sup.1) 0.771 Refinement R[F.sup.2 > 2 (F.sup.2)], 0.032, 0.087, 1.07 wR(F.sup.2), S No. of reflections 6337 No. of parameters 276 No. of restraints 7 H-atom treatment H atoms treated by a mixture of independent and constrained refinement .sub.max, .sub.min (e .sup.3) 0.47, 0.33

TABLE-US-00006 TABLE 6 Experimental details for Example 5 single crystal XRD Crystal data Chemical formula C.sub.12H.sub.17N.sub.4OSC.sub.6H.sub.4NO.sub.22.5(H.sub.2O) M.sub.r 432.39 Crystal system, space Triclinic, P1 group Temperature (K) 120 a, b, c () 13.0410 (7), 13.4469 (6), 15.5094 (8) , , () 113.0211 (17), 95.2862 (18), 110.5348 (16) V (.sup.3) 2259.6 (2) Z 4 Radiation type Mo K (mm.sup.1) 0.18 Crystal size (mm) 0.22 0.20 0.13 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.597, 0.746 No. of measured, 28170, 10518, 7599 independent and observed [I > 2(I)] reflections R.sub.int 0.059 (sin /).sub.max (.sup.1) 0.667 Refinement R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.070, 0.209, 1.03 No. of reflections 10518 No. of parameters 871 No. of restraints 1183 H-atom treatment H atoms treated by a mixture of independent and constrained refinement .sub.max, .sub.min (e .sup.3) 0.67, 0.48

Example 6: Thiamine Succinate: Dithiamine di(H-succinate) Monohydrate

[0043] ##STR00012##

[0044] In an analytical column, approximately 13 g of Amberlyst A26 OH form (Sigma Millipore) anion exchange resin was packed by gravity settling. The supplied hydroxyl anions were replaced by succinate anions with an aqueous solution of approximately 0.5M succinic acid (equivalent to 4.8 g succinic acid). The column was washed with approximately 100 mL purified water to remove unbound succinate. In the final step, 3 mL of 1M thiamine chloride solution was used to replace succinate in the anion column with chloride. The eluted solution containing thiamine cation and succinate anions was air dried at room temperature.

TABLE-US-00007 TABLE 7 Experimental details for Example 6 single crystal XRD Sample name Example 7 Crystal data Chemical formula 2(C.sub.4H.sub.5O.sub.4)2(C.sub.12H.sub.17N.sub.4OS)1.08(H.sub.2O) M.sub.r 784.33 Crystal system, space Triclinic, P1 group Temperature (K) 150 a, b, c () 10.4215 (4), 11.8581 (5), 16.4524 (7) , , () 91.9602 (13), 97.7888 (13), 114.2350 (11) V (.sup.3) 1827.78 (13) Z 2 Radiation type Cu K (mm.sup.1) 1.93 Crystal size (mm) 0.21 0.20 0.16 Data collection Diffractometer Bruker AXS D8 Quest CMOS diffractometer Absorption correction Multi-scan SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G. M. & Stalke D., J. Appl. Cryst. 48 (2015) 3-10 T.sub.min, T.sub.max 0.570, 0.754 No. of measured, 20997, 7328, 6372 independent and observed [I > 2(I)] reflections R.sub.int 0.036 (sin /).sub.max (.sup.1) 0.640 Refinement R[F.sup.2 > 2(F.sup.2)], wR(F.sup.2), S 0.055, 0.167, 1.18 No. of reflections 7328 No. of parameters 600 No. of restraints 321 H-atom treatment H atoms treated by a mixture of independent and constrained refinement .sub.max, .sub.min (e .sup.3) 0.39, 0.47

[0045] Computer programs for XRD: Apex3 v2016.9-0 (Bruker, 2016), SAINT V8.37A (Bruker, 2016), SHELXS97 (Sheldrick, 2008), SHELXL2017/1 (Sheldrick, 2015, 2017), SHELXLE Rev859 (Hbschle et al., 2011).

[0046] In thermogravimetric analysis, all the new salts/co-crystals disclosed here exhibit weight loss which can be attributed to chemical degradation at a lower temperature than the Cl, ClHCl, or NO.sub.3 salts. However, the degradation starts at a temperature no lower than 130, 105, and 115 C. for succinate, H-maleate Cl, and H-malonate Cl respectively. This allows their use as food additives.

[0047] Regarding dynamic moisture sorption, thiamine mononitrate is practically non-hygroscopic, but is considerably less soluble in water (2.7 g/100 ml) than the Cl (>30 g/100 ml) or ClHCl (>50 g/100 ml) salts. Thiamine Cl and Thiamine Cl HCl are very soluble, and show high hygroscopicity at 88%, and 95% RH, respectively. However, both these compounds exhibit instability in solution. The hygroscopic behaviour of new salts disclosed in the present disclosure is comparable to thiamine ClHCl, with elevated hygroscopicity seen at >95% RH for H-maleate Cl and 88% RH for H-malonate Cl.

[0048] Additional disclosure is found in Appendix A, filed herewith, entirety of which is incorporated herein by reference into the present disclosure

[0049] Those skilled in the art will recognize that numerous modifications can be made to the specific implementations described above. The implementations should not be limited to the particular limitations described. Other implementations may be possible.